Products
Indications
News & Events
Oxygen Biotherapeutics Secures Long-Term Clinical Supply of Oxycyte®
Company on Track to Resume Phase IIb Traumatic Brain Injury Trial Later This Year
MORRISVILLE, N.C., May 3, 2012 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT), a development stage biomedical company ("the Company") focused on developing perfluorocarbon-based intravenous and topical drug candidates, today announced it has achieved the critical milestone of securing an exclusive supply of cGMP-compliant Oxycyte®, the Company's proprietary perfluorocarbon based emulsion, that will take the Company through the current Phase II clinical trial for traumatic brain injury (TBI) and well into Phase III trials.
Key to this recent development was the signing of a contract with the manufacturer of cGMP-compliant FtBu, the proprietary, patent-protected active pharmaceutical ingredient in Oxycyte. Per the agreement, Oxygen Biotherapeutics has the exclusive rights to the supply of FtBu manufactured by this supplier. In addition, the Company is now aligned with a California-based contract manufacturer that will produce Oxycyte based on the Company's new scaled-up process for making the emulsion. Results from recent engineering batches made by this new supplier demonstrate that Oxycyte continues to meet all required specifications for product release. more..
Just Pure Oxygen Beauty.
Breathe new life into your skin with Dermacyte® oxygenating creams, our innovative skin care line that aims to deliver oxygen to your skin using our patented oxycyte technology. Backed by more than 15 years of research, Dermacyte® lets you moisturize your skin with oxygen without the use of hydrogen peroxide, known to cause free radical formation as well as dryness and thinning of the skin.
No chemical reactions. Paraben-free. Hypoallergenic.
For more information or to make a purchase, visit us at www.DermacyteUS.com.
O2 Elastin and Collagen – Dr. Gerald Klein talks about why oxygen is important for skin.